Roivant Sciences Ltd.
ROIV Large CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Roivant Sciences Ltd. en bref
Roivant Sciences Ltd. (ROIV) is currently trading at 27,43 € with a market capitalization of 19,7 Md €. The 52-week range spans from 9,35 € to 28,62 €; the current price is 4.1% below the yearly high. Year-over-year revenue growth stands at -66.7%.
💰 Dividende
Roivant Sciences Ltd. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
12 analystes évaluent Roivant Sciences Ltd. (ROIV) au consensus : Achat Fort. L'objectif de cours moyen est de 34,07 €, soit un potentiel de +24.22% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 27,49 € à 39,27 €.
Roivant Sciences Ltd. : la thèse d'investissement en détail
Roivant Sciences Ltd. (ROIV) operates in the Healthcare — specifically Biotechnology — and is headquartered in United Kingdom. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Strong Buy with an average price target implying roughly 24.22% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Revenue is contracting at -66.7% year-over-year — until that trend reverses, valuation is exposed to further downgrades.
À surveiller
- The share is trading at 93.8% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
- The analyst consensus price target implies 24.22% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 2.03)
- –CA en contraction (-66.7% sur un an)
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to market-like volatility, elevated short interest (6.64%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Roivant Sciences Ltd.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news